(Q24242101)

https://api.crossref.org/works/10.1002%2F14651858.CD006893

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Azathioprine for maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

What are the risks of serious infections and malignancies for patients treated with anti-tumor necrosis factor antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006893

7 January 2021